Insmed Incorporated

Equities

INSM

US4576693075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
24.8 ^USD	-0.48%		+1.97%	-19.97%

Apr. 23	Truist Starts Insmed at Buy With $48 Price Target, Sees Multi-Billion-Dollar Opportunities in Respiratory, Inflammatory Diseases	MT
Apr. 11	Barclays Adjusts Price Target on Insmed to $40 From $37, Maintains Overweight Rating	MT

Insmed Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

October 26, 2023 at 07:38 am EDT

Insmed Incorporated reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 158.93 million compared to USD 131.15 million a year ago. Basic loss per share from continuing operations was USD 1.11 compared to USD 1.09 a year ago.
For the nine months, net loss was USD 563.51 million compared to USD 321.41 million a year ago. Basic loss per share from continuing operations was USD 4.06 compared to USD 2.68 a year ago.

Latest news about Insmed Incorporated

Truist Starts Insmed at Buy With $48 Price Target, Sees Multi-Billion-Dollar Opportunities in Respiratory, Inflammatory Diseases	Apr. 23	MT
Barclays Adjusts Price Target on Insmed to $40 From $37, Maintains Overweight Rating	Apr. 11	MT
Insmed Incorporated to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference	Mar. 27	CI
Transcript : Insmed Incorporated Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 04:35 PM	Mar. 13
UBS Initiates Coverage on Insmed With Buy Rating, $46 Price Target	Feb. 27	MT
Transcript : Insmed Incorporated, Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Insmed's Q4 Loss Widens, Revenue Rises	Feb. 22	MT
Insmed Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Insmed Incorporated Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Insmed Incorporated Reiterates Sales Guidance for the Full-Year 2024	Feb. 22	CI
Wolfe Research Starts Insmed With Outperform Rating, $42 Price Target	Feb. 15	MT
Transcript : Insmed Incorporated Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 03:00 PM	Jan. 08
Insmed Insider Sold Shares Worth $620,089, According to a Recent SEC Filing	Jan. 05	MT
Insmed Incorporated Provides Sales Guidance for the Full Year 2023 and 2024	Jan. 05	CI
Insmed Insider Sold Shares Worth $395,970, According to a Recent SEC Filing	Dec. 22	MT
Transcript : Insmed Incorporated - Special Call	Nov. 16
Insmed Insider Sold Shares Worth $2,696,449, According to a Recent SEC Filing	23-10-31	MT
Mizuho Raises Price Target on Insmed to $35 From $33, Maintains Buy Rating	23-10-27	MT
Insmed's Shares Rise After It Reports Wider Q3 Net Loss, Higher Product Revenue	23-10-26	MT
Transcript : Insmed Incorporated, Q3 2023 Earnings Call, Oct 26, 2023	23-10-26
Insmed Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Insmed, Google Cloud Team up to Transform Life Sciences Using Generative AI	23-10-24	MT
Insmed Incorporated and Google Cloud Collaborate to Transform the Lives of Patients by Harnessing the Power of AI	23-10-24	CI
Cantor Fitzgerald Increases Price Target on Insmed to $54 From $46, Maintains Overweight Rating	23-09-21	MT
Transcript : Insmed Incorporated Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-11-2023 02:55 PM	23-09-11

Chart Insmed Incorporated

Duration

Period

More charts

Company Profile

Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Insmed Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.8 USD

Average target price

44.12 USD

Spread / Average Target

+77.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INSMED INCORPORATED	-19.97%	3.68B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs